News VBL craters as ovarian cancer gene therapy fails phase 3 test Phil Taylor gene therapy, ovarian cancer, VBL Therapeutics 0 Comment Shares in VBL Therapeutics have lost around 78% of their value in pre-market trading after the company reported Share X VBL craters as ovarian cancer gene therapy fails phase 3 test https://pharmaphorum.com/news/vbl-craters-as-ovarian-cancer-gene-therapy-fails-phase-3-test/
